{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:23:33Z","timestamp":1793877813458,"version":"4.7.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-025-05854-y","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T09:03:33Z","timestamp":1744016613000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Radiological extent predicts prognosis and relapse after acute exacerbation of interstitial lung disease in patients with rheumatoid arthritis: KEIO-RA-cohort"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1358-7069","authenticated-orcid":false,"given":"Koji","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5075-8977","authenticated-orcid":false,"given":"Mitsuhiro","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0001-1078","authenticated-orcid":false,"given":"Kanako","family":"Shimanuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-5765","authenticated-orcid":false,"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"5854_CR1","doi-asserted-by":"publisher","first-page":"103056","DOI":"10.1016\/j.autrev.2022.103056","volume":"21","author":"M Akiyama","year":"2022","unstructured":"Akiyama M, Kaneko Y (2022) Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease. Autoimmun Rev 21:103056. https:\/\/doi.org\/10.1016\/j.autrev.2022.103056","journal-title":"Autoimmun Rev"},{"key":"5854_CR2","doi-asserted-by":"publisher","first-page":"103501","DOI":"10.1016\/j.autrev.2023.103501","volume":"23","author":"M Akiyama","year":"2023","unstructured":"Akiyama M, Alshehri W, Kaneko Y (2023) Does a window of opportunity for rheumatoid arthritis-associated interstitial lung disease exist? Autoimmun Rev 23:103501. https:\/\/doi.org\/10.1016\/j.autrev.2023.103501","journal-title":"Autoimmun Rev"},{"key":"5854_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s00296-025-05789-4","volume":"45","author":"H Prasanna","year":"2025","unstructured":"Prasanna H, Inderjeeth CA, Nossent JC, Almutairi KB (2025) The global prevalence of interstitial lung disease in patients with rheumatoid arthritis: a systematic review and meta-analysis. Rheumatol Int 45:34. https:\/\/doi.org\/10.1007\/s00296-025-05789-4","journal-title":"Rheumatol Int"},{"key":"5854_CR4","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1136\/annrheumdis-2017-211138","volume":"76","author":"C Hyldgaard","year":"2017","unstructured":"Hyldgaard C, Hilberg O, Pedersen AB et al (2017) A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis 76:1700\u20131706. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211138","journal-title":"Ann Rheum Dis"},{"key":"5854_CR5","doi-asserted-by":"publisher","first-page":"e003132","DOI":"10.1136\/bmjopen-2013-003132","volume":"3","author":"H Hozumi","year":"2013","unstructured":"Hozumi H, Nakamura Y, Johkoh T et al (2013) Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study. BMJ Open 3:e003132. https:\/\/doi.org\/10.1136\/bmjopen-2013-003132","journal-title":"BMJ Open"},{"key":"5854_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12890-023-02532-2","volume":"23","author":"M Xie","year":"2023","unstructured":"Xie M, Zhu C, Ye Y (2023) Incidence, risk factors, and prognosis of acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis. BMC Pulm Med 23:255. https:\/\/doi.org\/10.1186\/s12890-023-02532-2","journal-title":"BMC Pulm Med"},{"key":"5854_CR7","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00296-016-3478-3","volume":"36","author":"M Akiyama","year":"2016","unstructured":"Akiyama M, Kaneko Y, Yamaoka K et al (2016) Association of disease activity with acute exacerbation of interstitial lung disease during Tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study. Rheumatol Int 36:881\u2013889. https:\/\/doi.org\/10.1007\/s00296-016-3478-3","journal-title":"Rheumatol Int"},{"key":"5854_CR8","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1093\/rheumatology\/keaa608","volume":"60","author":"S Izuka","year":"2021","unstructured":"Izuka S, Yamashita H, Iba A et al (2021) Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: clinical features and prognosis. Rheumatology 60:2348\u20132354. https:\/\/doi.org\/10.1093\/rheumatology\/keaa608","journal-title":"Rheumatology"},{"key":"5854_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12931-022-01978-y","volume":"23","author":"H Hozumi","year":"2022","unstructured":"Hozumi H, Kono M, Hasegawa H et al (2022) Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: mortality and its prediction model. Respir Res 23:57. https:\/\/doi.org\/10.1186\/s12931-022-01978-y","journal-title":"Respir Res"},{"key":"5854_CR10","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/rheumatology\/kead363","volume":"63","author":"Y Tanaka","year":"2024","unstructured":"Tanaka Y, Suzuki Y, Saku A et al (2024) Standardized 3D-CT lung volumes for patients with acute exacerbation of rheumatoid arthritis-associated interstitial lung disease. Rheumatology (Oxford) 63:1162\u20131171. https:\/\/doi.org\/10.1093\/rheumatology\/kead363","journal-title":"Rheumatology (Oxford)"},{"key":"5854_CR11","doi-asserted-by":"publisher","unstructured":"Morrisroe K, Hansen D, Stevens W et al (2023) Progressive pulmonary fibrosis and its impact on survival in systemic sclerosis-related interstitial lung disease. https:\/\/doi.org\/10.1093\/rheumatology\/kead491. Rheumatology","DOI":"10.1093\/rheumatology\/kead491"},{"key":"5854_CR12","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1093\/rheumatology\/keaa123","volume":"59","author":"M Shirakashi","year":"2020","unstructured":"Shirakashi M, Nakashima R, Tsuji H et al (2020) Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment. Rheumatology 59:3284\u20133292. https:\/\/doi.org\/10.1093\/rheumatology\/keaa123","journal-title":"Rheumatology"},{"key":"5854_CR13","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ et al (2010) 2010 Rheumatoid arthritis classification criteria: an American college of rheumatology\/european league against rheumatism collaborative initiative. Arthritis Rheum 62:2569\u20132581. https:\/\/doi.org\/10.1002\/art.27584","journal-title":"Arthritis Rheum"},{"key":"5854_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","volume":"80","author":"G Nagy","year":"2021","unstructured":"Nagy G, Roodenrijs NM, Welsing PM et al (2021) EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis 80:31\u201335. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217344","journal-title":"Ann Rheum Dis"},{"key":"5854_CR15","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD, Costabel U, Hansell DM et al (2013) An official American thoracic society\/European respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188:733\u2013748. https:\/\/doi.org\/10.1164\/rccm.201308-1483ST","journal-title":"Am J Respir Crit Care Med"},{"key":"5854_CR16","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1164\/rccm.200706-877oc","volume":"177","author":"NSL Goh","year":"2008","unstructured":"Goh NSL, Desai SR, Veeraraghavan S et al (2008) Interstitial lung disease in systemic sclerosis: A simple staging system. Am J Respir Crit Care Med 177:1248\u20131254. https:\/\/doi.org\/10.1164\/rccm.200706-877oc","journal-title":"Am J Respir Crit Care Med"},{"key":"5854_CR17","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW (2012) NIH image to imageJ: 25 years of image analysis. Nat Methods 9:671\u2013675. https:\/\/doi.org\/10.1038\/nmeth.2089","journal-title":"Nat Methods"},{"key":"5854_CR18","first-page":"S100","volume":"23","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Smolen J (2005) The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23:S100\u2013S108","journal-title":"Clin Exp Rheumatol"},{"key":"5854_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van \u2019t Hof MA, Kuper HH et al (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44\u201348. https:\/\/doi.org\/10.1002\/art.1780380107","journal-title":"Arthritis Rheum"},{"key":"5854_CR20","first-page":"789","volume":"9","author":"JF Fries","year":"1982","unstructured":"Fries JF, Spitz PW, Young DY (1982) The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 9:789\u2013793","journal-title":"J Rheumatol"},{"key":"5854_CR21","doi-asserted-by":"publisher","first-page":"106898","DOI":"10.1016\/j.rmed.2022.106898","volume":"200","author":"J Otsuka","year":"2022","unstructured":"Otsuka J, Yoshizawa S, Kudo K et al (2022) Clinical features of acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: comparison with idiopathic pulmonary fibrosis. Respir Med 200:106898. https:\/\/doi.org\/10.1016\/j.rmed.2022.106898","journal-title":"Respir Med"},{"key":"5854_CR22","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00296-023-05313-6","volume":"43","author":"GM Koduri","year":"2023","unstructured":"Koduri GM, Podlasek A, Pattapola S et al (2023) Four-factor risk score for the prediction of interstitial lung disease in rheumatoid arthritis. Rheumatol Int 43:1515\u20131523. https:\/\/doi.org\/10.1007\/s00296-023-05313-6","journal-title":"Rheumatol Int"},{"key":"5854_CR23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1080\/14397595.2018.1442170","volume":"29","author":"Y Ito","year":"2018","unstructured":"Ito Y, Arita M, Kumagai S et al (2018) Radiological fibrosis score is strongly associated with worse survival in rheumatoid arthritis-related interstitial lung disease. Mod Rheumatol 29:98\u2013104. https:\/\/doi.org\/10.1080\/14397595.2018.1442170","journal-title":"Mod Rheumatol"},{"key":"5854_CR24","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.ijbiomac.2021.06.140","volume":"184","author":"A Sheinenzon","year":"2021","unstructured":"Sheinenzon A, Shehadeh M, Michelis R et al (2021) Serum albumin levels and inflammation. Int J Biol Macromol 184:857\u2013862. https:\/\/doi.org\/10.1016\/j.ijbiomac.2021.06.140","journal-title":"Int J Biol Macromol"},{"key":"5854_CR25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2018-06-856500","volume":"133","author":"G Weiss","year":"2019","unstructured":"Weiss G, Ganz T, Goodnough LT (2019) Anemia of inflammation. Blood 133:40\u201350. https:\/\/doi.org\/10.1182\/blood-2018-06-856500","journal-title":"Blood"},{"key":"5854_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12979-023-00410-3","volume":"21","author":"Y Pan","year":"2024","unstructured":"Pan Y, Ma L (2024) Inflammatory markers and physical frailty: towards clinical application. Immun Ageing 21:4. https:\/\/doi.org\/10.1186\/s12979-023-00410-3","journal-title":"Immun Ageing"},{"key":"5854_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41584-023-00921-9","volume":"19","author":"JL Bennett","year":"2023","unstructured":"Bennett JL, Pratt AG, Dodds R et al (2023) Rheumatoid sarcopenia: loss of skeletal muscle strength and mass in rheumatoid arthritis. Nat Rev Rheumatol 19:239\u2013251. https:\/\/doi.org\/10.1038\/s41584-023-00921-9","journal-title":"Nat Rev Rheumatol"},{"key":"5854_CR28","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s12877-019-1253-5","volume":"19","author":"VA van Atteveld","year":"2019","unstructured":"van Atteveld VA, Van Ancum JM, Reijnierse EM et al (2019) Erythrocyte sedimentation rate and albumin as markers of inflammation are associated with measures of sarcopenia: a cross-sectional study. BMC Geriatr 19:233. https:\/\/doi.org\/10.1186\/s12877-019-1253-5","journal-title":"BMC Geriatr"},{"key":"5854_CR29","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/art.40904","volume":"71","author":"JA Sparks","year":"2019","unstructured":"Sparks JA, He X, Huang J et al (2019) Rheumatoid arthritis disease activity predicting incident clinically apparent rheumatoid arthritis-associated interstitial lung disease: A prospective cohort study. Arthritis Rheumatol 71:1472\u20131482. https:\/\/doi.org\/10.1002\/art.40904","journal-title":"Arthritis Rheumatol"},{"key":"5854_CR30","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.4049\/jimmunol.1900473","volume":"203","author":"EK Wu","year":"2019","unstructured":"Wu EK, Henkes ZI, McGowan B et al (2019) TNF-induced interstitial lung disease in a murine arthritis model: accumulation of activated monocytes, conventional dendritic cells, and CD21+\/CD23- B cell follicles is prevented with anti-TNF therapy. J Immunol 203:2837\u20132849. https:\/\/doi.org\/10.4049\/jimmunol.1900473","journal-title":"J Immunol"},{"key":"5854_CR31","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1165\/rcmb.2002-0262OC","volume":"29","author":"YP Moodley","year":"2003","unstructured":"Moodley YP, Misso NLA, Scaffidi AK et al (2003) Inverse effects of interleukin-6 on apoptosis of fibroblasts from pulmonary fibrosis and normal lungs. Am J Respir Cell Mol Biol 29:490\u2013498. https:\/\/doi.org\/10.1165\/rcmb.2002-0262OC","journal-title":"Am J Respir Cell Mol Biol"},{"key":"5854_CR32","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1093\/rheumatology\/keaa621","volume":"59","author":"C Fern\u00e1ndez-D\u00edaz","year":"2020","unstructured":"Fern\u00e1ndez-D\u00edaz C, Casta\u00f1eda S, Melero-Gonz\u00e1lez RB et al (2020) Abatacept in interstitial lung disease associated with rheumatoid arthritis: National multicenter study of 263 patients. Rheumatology (Oxford) 59:3906\u20133916. https:\/\/doi.org\/10.1093\/rheumatology\/keaa621","journal-title":"Rheumatology (Oxford)"},{"key":"5854_CR33","doi-asserted-by":"publisher","first-page":"103636","DOI":"10.1016\/j.autrev.2024.103636","volume":"23","author":"J Narv\u00e1ez","year":"2024","unstructured":"Narv\u00e1ez J, Aguilar-Coll M, Roig-Kim M et al (2024) Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis. Autoimmun Rev 23:103636. https:\/\/doi.org\/10.1016\/j.autrev.2024.103636","journal-title":"Autoimmun Rev"},{"key":"5854_CR34","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s10238-024-01448-3","volume":"24","author":"P-C Shih","year":"2024","unstructured":"Shih P-C, Lai C-C, Zou Q-H et al (2024) Abatacept versus tumor necrosis factor inhibitors on mortality and medical utilizations in the treatment of rheumatoid arthritis associated interstitial lung disease: a large-scale real-world retrospective cohort study. Clin Exp Med 24:186. https:\/\/doi.org\/10.1007\/s10238-024-01448-3","journal-title":"Clin Exp Med"},{"key":"5854_CR35","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/pc2kq1","author":"K Suzuki","year":"2024","unstructured":"Suzuki K, Akiyama M, Kaneko Y (2024) Long-term efficacy of sarilumab on the progression of interstitial lung disease in rheumatoid arthritis: the KEIO-RA cohort and literature review. Clin Exp Rheumatol. https:\/\/doi.org\/10.55563\/clinexprheumatol\/pc2kq1","journal-title":"Clin Exp Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05854-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-025-05854-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05854-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T09:39:45Z","timestamp":1744709985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-025-05854-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["5854"],"URL":"https:\/\/doi.org\/10.1007\/s00296-025-05854-y","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.A. has received speaking fees from AbbVie, Asahi-Kasei, Astellas, Boehringer Ingelheim, Chugai, Eisai, Eli Lilly, Janssen, Novartis, Pfizer, Taisho, UCB, Gilead Sciences. Y. K. has received research grants from AbbVie, Eisai, Sanofi, Chugai, Mitsubishi-Tanabe, Taisho, and has received scholarship grant from Asahi-Kasei, Eisai, Boehringer Ingelheim, Taisho, and has received speaking fees from AbbVie, Asahi-Kasei, Astellas, Ayumi Pharmaceutical Corporation, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Glaxo Smith Kline, Janssen, Novartis, Pfizer, UCB, Gilead Sciences. K.S. declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"92"}}